Free Trial
→ Must-See: 5-Second Trump Prediction (From InvestorPlace) (Ad)

Vaxcyte Q1 2023 Earnings Report

Vaxcyte logo
$85.30 -2.53 (-2.88%)
As of 01/17/2025 04:00 PM Eastern
Earnings HistoryForecast

Vaxcyte EPS Results

Actual EPS
-$0.70
Consensus EPS
-$0.80
Beat/Miss
Beat by +$0.10
One Year Ago EPS
N/A

Vaxcyte Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Vaxcyte Announcement Details

Quarter
Q1 2023
Date
5/8/2023
Time
N/A

Conference Call Resources

Powered by Quartr

Vaxcyte Earnings Headlines

Why Vaxcyte, Inc. (PCVX) Is One of the Best Russell 2000 Stocks to Invest in According to Analysts?
January 18 at 7:57 PM | msn.com
Brokers Set Expectations for Vaxcyte FY2029 Earnings
January 16, 2025 | americanbankingnews.com
Must-See: 5-Second Trump Prediction
President Trump's prediction is about to become a reality... Opening a rare window of opportunity for you to accelerate your retirement during the first 100 days of his administration.
January 20, 2025 | InvestorPlace (Ad)
Vaxcyte’s VAX-A1 Vaccine: A Promising Contender in the Global Fight Against Group A Strep
January 15, 2025 | markets.businessinsider.com
Kuehn Law Encourages Investors of Vaxcyte, Inc. to Contact Law Firm
January 7, 2025 | prnewswire.com
Is Vaxcyte, Inc. (PCVX) the Best Performing Biotech Stock in 2024?
December 23, 2024 | msn.com
See More Vaxcyte Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Vaxcyte? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Vaxcyte and other key companies, straight to your email.

About Vaxcyte

Vaxcyte (NASDAQ:PCVX), a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine for the prevention of invasive pneumococcal disease. The company also develops VAX-31 to protect against emerging strains and to help address antibiotic resistance; VAX-A1, a novel conjugate vaccine candidate to prevent disease caused by Group A Streptococcus; VAX-PG, a novel protein vaccine candidate targeting keystone pathogen responsible for periodontitis; and VAX-GI to prevent Shigella, a bacterial illness. The company was formerly known as SutroVax, Inc. and changed its name to Vaxcyte, Inc. in May 2020. Vaxcyte, Inc. was incorporated in 2013 and is headquartered in San Carlos, California.

View Vaxcyte Profile

More Earnings Resources from MarketBeat

Earnings Tools
Earnings By Country
Latest Articles